Image

A Clinical Study of SPH9788 Tablets in Healthy Chinese Subjects.

A Clinical Study of SPH9788 Tablets in Healthy Chinese Subjects.

Recruiting
18-45 years
All
Phase 1

Powered by AI

Overview

The purpose of the study is to evaluate the safety of SPH9788 tablets in healthy subjects.

Eligibility

Inclusion Criteria:

  1. Healthy male and female subjects aged from 18 to 45 years;
  2. Subject has a Body Mass Index (BMI) between 18.5 and 28.0 kg/m2 at screening and the weight of male subjects is not less than 50 kg, and the weight of female subjects is not less than 45 kg;;
  3. Subjects who voluntarily participate and sign informed consent form;
  4. Subjects who can communicate well with investigator and comply with the lifestyle restrictions specified in the protocol, and cooperate to complete the trial procedure;
  5. Subjects willing to use reliable contraceptive methods throughout the trial and for 6 months after trial completion.

Exclusion Criteria:

  1. Medical history (current or past) that in the investigator's judgment may interfere with trial participation;
  2. Surgical/medical conditions that may significantly affect drug pharmacokinetics (absorption, distribution, metabolism, excretion) or pose safety risks;
  3. Occurrence of protocol-defined exclusionary events within 3 months prior to investigational product administration;
  4. Use of any prescription/non-prescription medications (including herbal products) within 2 weeks prior to dosing;
  5. Known hypersensitivity to any component of the investigational product or history of severe allergic reactions;
  6. Positive serology for hepatitis B surface antigen, hepatitis C antibody, HIV antibody, and syphilis serum reaction;
  7. Substance abuse history within 1 year prior to screening or positive urine drug screen;
  8. Alcohol abuse history within 1 year or positive alcohol breath test;
  9. Smoking ≥5 cigarettes/day on average during 3 months prior to screening;
  10. Pregnant or lactating women;
  11. Positive pregnancy test before study drug administration, or male and female subjects who refuse to use effective contraceptive methods during and for 6 months post-trial, or who have plans to donate sperm or eggs;
  12. Poor compliance or any other condition that in the investigator's opinion renders the subject unsuitable for trial participation.

Study details
    Healthy Participants

NCT06839131

Shanghai Pharmaceuticals Holding Co., Ltd

15 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.